ГЕННАЯ КЛЕТОЧНАЯ ТЕРАПИЯ ВИЧ И ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КРОВЕТВОРНОЙ И ЛИМФАТИЧЕСКОЙ ТКАНИ НА ОСНОВЕ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК С ИСПОЛЬЗОВАНИЕМ САЙТ-СПЕЦИФИЧЕСКОГО РЕДАКТИРОВАНИЯ ГЕНОМА
Standard
ГЕННАЯ КЛЕТОЧНАЯ ТЕРАПИЯ ВИЧ И ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КРОВЕТВОРНОЙ И ЛИМФАТИЧЕСКОЙ ТКАНИ НА ОСНОВЕ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК С ИСПОЛЬЗОВАНИЕМ САЙТ-СПЕЦИФИЧЕСКОГО РЕДАКТИРОВАНИЯ ГЕНОМА. / Popova, Marina; Sergeev, Vladislav S; Lepik, Kirill; Shakirova, Alena; Potter, A; Barkhatov, Ildar M.; Fehse, Boris; Afanasyev, Boris V. .
in: Zhurnal infektologii, Jahrgang 9, Nr. 1, 2017, S. 31-39.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - ГЕННАЯ КЛЕТОЧНАЯ ТЕРАПИЯ ВИЧ И ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КРОВЕТВОРНОЙ И ЛИМФАТИЧЕСКОЙ ТКАНИ НА ОСНОВЕ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК С ИСПОЛЬЗОВАНИЕМ САЙТ-СПЕЦИФИЧЕСКОГО РЕДАКТИРОВАНИЯ ГЕНОМА
AU - Popova, Marina
AU - Sergeev, Vladislav S
AU - Lepik, Kirill
AU - Shakirova, Alena
AU - Potter, A
AU - Barkhatov, Ildar M.
AU - Fehse, Boris
AU - Afanasyev, Boris V.
PY - 2017
Y1 - 2017
N2 - Based on the annual UNAIDS reports the number of HIV-infected patients is continually growing since 1983. Antiretroviral Therapy (ART) allows to prolong life expectancy, but the problem of life quality and overall survival is still remaining. Nowadays, in the era of ART, one of the main cause of mortality in HIV-infected patients is malignancies. Lymphomas play one of the key roles in this group of diseases. The treatment of lymphomas includes combined regiments of chemotherapy with a curative potential. High dose chemotherapywith autologous hematopoietic stem cell transplant (auto-HSCT) is the main path of the treatment for relapsed / refractory lymphomas. In the last few years with a development of the genome editing technology auto-HSCT is becoming one of the most promising methods of HIV treatment. The case of “Berlin patient” when allogeneic HSCT from donor with mutation CCR5-delta32 lead to cure from HIV and proof of concept the efficacy of the gene therapy for HIV based on HSCT. Hematopoietic stem cell transplantation with edited autologous HSC (CCR5 knockout by site-specific genome editing tools with engineering nucleases) is a comprehensive treatment for this cohort of patients. On one hand, high dosechemotherapy with auto-HSCT cures the malignancy; on the other hand auto-HSCT works as a delivery method for the edited cells and creates an environment for the HIV eradication. This review is dedicated to HIV and oncology, methodsof treatment of hematological malignancies and HIV-infection using genome editing technology based on HSCT.
AB - Based on the annual UNAIDS reports the number of HIV-infected patients is continually growing since 1983. Antiretroviral Therapy (ART) allows to prolong life expectancy, but the problem of life quality and overall survival is still remaining. Nowadays, in the era of ART, one of the main cause of mortality in HIV-infected patients is malignancies. Lymphomas play one of the key roles in this group of diseases. The treatment of lymphomas includes combined regiments of chemotherapy with a curative potential. High dose chemotherapywith autologous hematopoietic stem cell transplant (auto-HSCT) is the main path of the treatment for relapsed / refractory lymphomas. In the last few years with a development of the genome editing technology auto-HSCT is becoming one of the most promising methods of HIV treatment. The case of “Berlin patient” when allogeneic HSCT from donor with mutation CCR5-delta32 lead to cure from HIV and proof of concept the efficacy of the gene therapy for HIV based on HSCT. Hematopoietic stem cell transplantation with edited autologous HSC (CCR5 knockout by site-specific genome editing tools with engineering nucleases) is a comprehensive treatment for this cohort of patients. On one hand, high dosechemotherapy with auto-HSCT cures the malignancy; on the other hand auto-HSCT works as a delivery method for the edited cells and creates an environment for the HIV eradication. This review is dedicated to HIV and oncology, methodsof treatment of hematological malignancies and HIV-infection using genome editing technology based on HSCT.
U2 - 10.22625/2072-6732-2017-9-1-31-39
DO - 10.22625/2072-6732-2017-9-1-31-39
M3 - SCORING: Zeitschriftenaufsatz
VL - 9
SP - 31
EP - 39
JO - Zhurnal infektologii
JF - Zhurnal infektologii
SN - 2072-6732
IS - 1
ER -